GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotron Ltd (OTCPK:BITRF) » Definitions » Change In Payables And Accrued Expense

Biotron (Biotron) Change In Payables And Accrued Expense : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Biotron Change In Payables And Accrued Expense?

Biotron's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Biotron's Accounts Payable & Accrued Expense stayed the same from Jun. 2023 to Dec. 2023 .

Biotron's Change In Payables And Accrued Expense for the fiscal year that ended in Jun. 2023 was $0.00 Mil. It means Biotron's Accounts Payable & Accrued Expense stayed the same from Jun. 2022 to Jun. 2023 .


Biotron Change In Payables And Accrued Expense Historical Data

The historical data trend for Biotron's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotron Change In Payables And Accrued Expense Chart

Biotron Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biotron Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biotron Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotron Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Biotron's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotron (Biotron) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotron Ltd (OTCPK:BITRF) » Definitions » Change In Payables And Accrued Expense
Traded in Other Exchanges
Address
56 Delhi Road, Suite 3.3, North Ryde, Sydney, NSW, AUS, 2113
Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.

Biotron (Biotron) Headlines

From GuruFocus

Biotron Drug Effective Against COVID-19 In Animals

By PRNewswire PRNewswire 11-25-2021